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Abstract PTEN controls three-dimensional (3D) glandular morphogenesis by coupling
juxtamembrane signaling to mitotic spindle machinery. While molecular mechanisms remain
unclear, PTEN interacts through its C2 membrane-binding domain with the scaffold protein b-
Arrestin1. Because b-Arrestin1 binds and suppresses the Cdc42 GTPase-activating protein
ARHGAP21, we hypothesize that PTEN controls Cdc42 -dependent morphogenic processes
through a b-Arrestin1-ARHGAP21 complex. Here, we show that PTEN knockdown (KD) impairs b-
Arrestin1 membrane localization, b-Arrestin1-ARHGAP21 interactions, Cdc42 activation, mitotic
spindle orientation and 3D glandular morphogenesis. Effects of PTEN deficiency were phenocopied
by b-Arrestin1 KD or inhibition of b-Arrestin1-ARHGAP21 interactions. Conversely, silencing of
ARHGAP21 enhanced Cdc42 activation and rescued aberrant morphogenic processes of PTEN-
deficient cultures. Expression of the PTEN C2 domain mimicked effects of full-length PTEN but a
membrane-binding defective mutant of the C2 domain abrogated these properties. Our results
show that PTEN controls multicellular assembly through a membrane-associated regulatory protein
complex composed of b-Arrestin1, ARHGAP21 and Cdc42.
DOI: https://doi.org/10.7554/eLife.24578.001
Introduction
PTEN (phosphatase and tensin homolog) is the second most commonly mutated tumor suppressor
gene in human cancer (Cantley and Neel, 1999) and has a central role in multicellular morphogene-
sis (Martin-Belmonte et al., 2007; Jagan et al., 2013a; Deevi et al., 2016). While PTEN antago-
nizes the phosphoinositol 3-kinase (PI3K)/AKT pathway via its N-terminal phosphatase domain
(Cantley and Neel, 1999), three-dimensional (3D) multicellular assembly was unaffected by forced
variation of PI3K activity in colorectal organotypic model systems (Jagan et al., 2013a;
Magudia et al., 2012). The PTEN domain structure includes an N-terminal phosphatase domain, a
C2 domain, a C-terminal tail and a PDZ-binding domain. The C2 domain binds to membrane phos-
pholipids by inserting a hydrophobic (CBR3) loop into the membrane bilayer and thereby provides a
scaffold for juxtamembrane signaling (Lee et al., 1999). Furthermore, the PTEN C2 domain regu-
lates polarized migration (Raftopoulou and Hall, 2004), multicellular morphology (Leslie et al.,
2007; Jagan et al., 2013b) and has an important but poorly understood tumor suppressor function
(Caserta et al., 2015).
Within complex systems, protein scaffolding enhances signaling efficiency by assembly of spatially
distinct subcellular complexes for different cellular tasks (Weng et al., 1999; Pertz, 2010). The
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PTEN C2 domain binds the plasma membrane and interacts with the scaffold protein b-Arrestin1
(Lima-Fernandes et al., 2011) that in turn binds and suppresses ARHGAP21 (Anthony et al., 2011),
a member of a highly conserved class of RhoGAPs (Bos et al., 2007; Anderson et al., 2008). ARH-
GAP21 regulates the small GTPases, Cdc42 (Dubois et al., 2005) and RhoA (Anthony et al., 2011).
These GTPases have overlapping, complementary functions required for mitotic spindle orientation
and consequent control of the cell division axis, cytokinetic furrow positioning, daughter cell size
and tissue morphogenesis (Morin and Bellaı¨che, 2011). Both Cdc42 and RhoA drive actin nucleation
and cortical stiffening (Ma et al., 1998; Eisenmann et al., 2007) required for spindle orientation
(Johnston et al., 2013). Furthermore, Cdc42 crosstalk with protein kinase c zeta [PRKCZ]
(Noda et al., 2001; Durgan et al., 2011) localizes force generators within the cell cortex that act via
astral microtubules to orientate the spindle (Hao et al., 2010). ARHGAP21 has high GAP activity for
Cdc42 (Dubois et al., 2005) and its Pac-1 homologue regulates multicellular patterning in
C. elegans by spatial regulation of Cdc42 (Anderson et al., 2008; Klompstra et al., 2015).
Here, we investigate PTEN spatiotemporal coordination of mammalian glandular morphogenesis
through conserved juxtamembrane b-Arrestin1-ARHGAP21 interactions, using 3D colorectal cancer
(CRC) model systems. To substantiate physiological relevance of these processes, we also investi-
gate their role in morphogenesis of 3D multicellular organoids isolated from normal colon.
Results
PTEN regulates b-Arrestin1 membrane localization
b-Arrestin1 scaffolds juxtamembrane signaling networks (Kovacs et al., 2009), binds ARHGAP21
(Anthony et al., 2011) and governs PTEN catalytic and noncatalytic functions (Lima-
Fernandes et al., 2011). To ascertain whether PTEN regulates membrane-associated b-Arrestin1
and ARHGAP21, we conducted expression and simple fractionation studies in PTEN-expressing
[Caco-2 and HCT116] and -deficient [Caco-2 ShPTEN (ShPTEN) and PTEN -/- HCT116 (PTEN -/-)] cells.
We found near-significant or significant differences of total lysate b-Arrestin1 and ARHGAP21
between PTEN-expressing and -deficient cells [Caco-2 vs ShPTEN (Figure 1A,B) and HCT116 vs
PTEN -/- cells (Figure 1—figure supplements 1 and 2)]. To infer subcellular localization of b-
Arrestin1 and ARHGAP21, we performed membrane fractionation studies and normalized each
eLife digest The protein PTEN helps to organize cells in the body to form complex structures.
In particular, it collects signals from a cells’ surroundings and changes where cells divide so new cells
are produced in the right places. The control of cell division by PTEN is also thought to help limit
the progression and spread of cancer.
PTEN can interact with another protein called b-Arrestin1, which behaves as a so-called
scaffolding protein – in other words, one that helps groups of proteins to interact with each other. b-
Arrestin1 has been found to control cell division via a series of other proteins, including ARHGAP21
and Cdc42. The relationship between PTEN and these other proteins in dividing cells is still not fully
understood.
Javadi, Deevi et al. studied PTEN in human cells grown in the laboratory to show that a part of
PTEN known as the C2 domain allows it to help organize cells by moving b-Arrestin1 to the outer
edge of the cell – the cell membrane. This relocation allows b-Arrestin1 to interact with ARHGAP21
and Cdc42, and control cell division. Active Cdc42 changes the orientation of cell division, allowing
cells to organize into single layers of regular cells and similar tightly controlled structures.
Further experiments revealed that these proteins are important to form tubes inside the glands
of the gut. The C2 region of PTEN also helps to detect signals carried by fat molecules in the cell
membrane, so these results provide a direct link between signaling and cell organization via PTEN.
The work of Javadi, Deevi et al. provides new understanding of how PTEN links nutrient availability
to cell organization during development and may also lead to new insights into the role of PTEN in
limiting the growth of tumors.
DOI: https://doi.org/10.7554/eLife.24578.002
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Figure 1. PTEN enhances membrane recruitment of b-Arrestin1. (A,B) Total lysate b-Arrestin1 and ARHGAP21 expression in ShPTEN vs Caco-2
(control). GAPDH loading control; b-Arrestin1 = 0.78 ± 0.06; p=NS (0.08); ARHGAP21 = 1.29 ± 0.05;*p=0.03. (C) Cytosol and membrane localization of b-
Arrestin1 and ARHGAP21 in control Caco-2 or Caco-2 ShPTEN (ShPTEN) cells. E-Cadherin and HSP90 used as cell membrane or cytosol markers. (D)
Summary b-Arrestin1 and ARHGAP21 membrane ADU in ShPTEN cells vs Caco-2 control. Membrane values are normalized against total lysate ADU
Figure 1 continued on next page
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protein’s densitometry value against its total lysate level, to investigate relative proportions of b-
Arrestin1 and ARHGAP21 associated with membrane. We found greater b-Arrestin1 but lower ARH-
GAP21 levels in Caco-2 than in ShPTEN membrane fractions (Figure 1C,D). As b-Arrestins are known
to localize to activated lysophosphatidic acid receptors [LPARs] (Urs et al., 2005; Li et al., 2009)
that are expressed in Caco-2 and HCT116 cell membranes (Yun et al., 2005), we investigated effects
of PTEN on lysophosphatidic acid (LPA)-induced membrane recruitment of b-Arrestin1. We found
greater LPA-mediated membrane enrichment of b-Arrestin1 in Caco-2 and HCT116 cells than in
PTEN-deficient ShPTEN or PTEN -/- HCT116 (PTEN -/-) subclones (Figure 1E,F; Figure 1—figure
supplements 3 and 4). We next used confocal microscopy to determine PTEN effects on b-Arrestin1
subcellular distribution in whole cells. We expressed the b-Arrestin1-mCherry fusion protein and
mCherry only controls in PTEN-expressing and -deficient cells. We assessed colocalization with Alexa
488-labeled wheat germ agglutinin (WGA), a widely used fluorescent probe for cell and Golgi com-
plex membranes (Crossman et al., 2015) by confocal microscopy. b-Arrestin1-mCherry was predom-
inantly cytosolic in vehicle only (VO)-treated cells, in accord with cytosolic accumulation of unlabelled
b-Arrestin1 in fractionation studies. On treatment with LPA, the b-Arrestin1-mCherry fusion protein
colocalized with WGA at the plasma membrane in PTEN-expressing Caco-2 and HCT116 control
cells (Figure 1G; Figure 1—figure supplement 5). Line scanning analysis revealed overlap of b-
Arrestin1-mCherry and Alexa 488 fluorescence signals in plasma membrane peaks in PTEN-express-
ing Caco-2 and HCT116 cells after LPA treatment (Figure 1G; Figure 1—figure supplement 5).
Figure 1 continued
values for each protein (b-Arrestin1 = 0.82 ± 0.03 *p<0.05; ARHGAP21 = 1.48 ± 0.05 **p<0.01). (E) b-Arrestin1 expression in membrane fractions of
control Caco-2 and ShPTEN cells after treatment. (F) Summary fold change of membrane b-Arrestin1 after LPA (+) or VO [vehicle only(-)] treatment
shown in (E) ;Caco-2 (+) vs (-)=1.74 ± 0.09; **p<0.01; ShPTEN (+) vs ShPTEN (-)=0.97 ± 0.08 vs 0.66 ± 0.07;*p<0.05 values expressed as fold change
relative to Caco-2 (-) control. ShPTEN (-) vs Caco-2 (-)=0.66 ± 0.07;*p<0.05; ShPTEN (+) vs Caco-2 (+)=0.97 ± 0.08 vs 1.74 ± 0.09;**p<0.01. Green bars
indicate ShPTEN cells. (G) Plasma membrane localization of the b-Arrestin1-mCherry fusion protein in Caco-2 control (top two panels) or ShPTEN
(bottom two panels) after VO (-) or LPA (+) treatment. Red and green fluorescence emitted by m-Cherry and Alexa 488 labels correspond to b-Arrestin1
and WGA, respectively. Note WGA localization to plasma membranes and Golgi apparatus. Colocalization of b-Arrestin1 and WGA at the plasma
membrane revealed by composite yellow signal in Merge, Z-stack images and by overlap of fluorescence intensity curves in line scans. Horizontal yellow
bars indicate focal plane. All experiments in triplicate. Analyses by Student’s paired t test or ANOVA with Tukey post hoc test. White scale bar 20 mm.
Molecular weights indicated by arrows in blots.
DOI: https://doi.org/10.7554/eLife.24578.003
The following source data and figure supplements are available for figure 1:
Source data 1. Source data for Figure 1B.
DOI: https://doi.org/10.7554/eLife.24578.010
Source data 2. Source data for Figure 1D.
DOI: https://doi.org/10.7554/eLife.24578.011
Source data 3. Source data for Figure 1F.
DOI: https://doi.org/10.7554/eLife.24578.012
Figure supplement 1. Total b-Arrestin1 and ARHGAP21 expression in control HCT116 and PTEN -/- cell lysates.
DOI: https://doi.org/10.7554/eLife.24578.004
Figure supplement 2. Cell lysate expression of b-Arrestin1 and ARHGAP21 shown in Figure 1—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.24578.005
Figure supplement 2—source data 1. . Figure 1—figure supplement 2 Beta-Arestin1 and ARHGAP21 expression in HCT116 clones -Source data.
DOI: https://doi.org/10.7554/eLife.24578.013
Figure supplement 3. Treatment effects on membrane b-Arrestin1 in HCT116 control vs PTEN -/- cells.
DOI: https://doi.org/10.7554/eLife.24578.006
Figure supplement 4. Treatment effects on membrane b-Arrestin1 shown in Figure 1—figure supplement 3.
DOI: https://doi.org/10.7554/eLife.24578.007
Figure supplement 4—source data 1. Figure 1—figure supplement 4 LPA effects on Beta-Arrestin1 in HCT116 clones.
DOI: https://doi.org/10.7554/eLife.24578.014
Figure supplement 5. Plasma membrane localization of the b-Arrestin1-mCherry fusion protein in HCT116 control (top two panels) or PTEN -/- cells
(bottom two panels) after VO (-) or LPA (+) treatment.
DOI: https://doi.org/10.7554/eLife.24578.008
Figure supplement 6. Control mCherry distribution in HCT116 and PTEN -/- cells.
DOI: https://doi.org/10.7554/eLife.24578.009
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While LPA had limited effects in ShPTEN cells that have residual low level PTEN (Figure 1G), this
treatment had no effects on b-Arrestin1-mCherry subcellular distribution in PTEN-null (PTEN -/-) cells
(Figure 1—figure supplement 5). mCherry only did not localize at the plasma membrane (data
shown for control PTEN-expressing HCT116 and PTEN -/- cells only; Figure 1—figure supplement
6). To exclude a non-specific effect of PTEN on ligand-mediated protein translocation to the cell
membrane, we investigated 1,25(OH)2D3-mediated membrane localization of E-Cadherin
(Pa´lmer et al., 2001) in Caco-2 and ShPTEN cells. We found that 1,25(OH)2D3 treatment induced
equivalent E-Cadherin translocation to the plasma membrane in PTEN-expressing and -deficient
cells, compared to control VO treatment (data not shown). Collectively, these findings show that
PTEN functions within a regulatory scaffolding network that couples b-Arrestin1 to ARHGAP21 at
the plasma membrane.
PTEN controls Cdc42-dependent epithelial morphogenesis through b-
Arrestin1-ARHGAP21 interactions
Within signaling scaffolds, b-Arrestin1 regulates monomeric GTPases (Barnes et al., 2005) and
orchestrates cytoskeletal rearrangements (Ge et al., 2003). We investigated b-Arrestin1-ARHGAP21
coregulation of Cdc42, mitotic spindle orientation and morphogenesis in 3D organotypic model sys-
tems. SiRNA knockdown (KD) of b-Arrestin1 in control PTEN-expressing Caco-2 cells suppressed
Cdc42 activation as assessed by Cdc42-GTP levels in cell lysates on Western blots (Figure 2A,B). In
contrast, siRNA KD of ARHGAP21 enhanced Cdc42 activation in PTEN-deficient cells (Figure 2C,D).
During normal organotypic 3D glandular morphogenesis, mitotic spindle planes are orientated at
approximately right angles to gland centres (GCs) by Cdc42-dependent mechanisms. Conversely,
ShPTEN cells show deficiencies of these processes (Jagan et al., 2013a; Deevi et al., 2016;
Jagan et al., 2013b). In 3D Caco-2 cultures, SiRNA b-Arrestin1 KD suppressed Cdc42-GTP
(Figure 2E,F), induced mitotic spindle misorientation and abnormal multilumen formation
(Figure 2E, Figure 2—figure supplements 1 and 2). Conversely, ARHGAP21 KD enhanced Cdc42-
GTP (Figure 2G,H), restored mitotic spindle orientation and promoted single lumen formation in 3D
ShPTEN cultures (Figure 2G, Figure 2—figure supplements 3 and 4). Because of the previously
reported relationship between ARHGAP21 and RhoA (Lima-Fernandes et al., 2011), we assessed
relationships between b-Arrestin1, ARHGAP21 and RhoA. We found that activation of RhoA related
directly to b-Arrestin1 and inversely to ARHGAP21 expression. b-Arrestin1 and RhoA-GTP were sup-
pressed, while ARHGAP21 expression was enhanced by PTEN knockdown (data for RhoA-GTP not
shown). Taken together, these data indicate that PTEN regulates b-Arrestin1-ARHGAP21 interac-
tions to control GTPase signaling, mitotic spindle orientation and 3D multicellular morphology.
PTEN promotes b-Arrestin1 and ARHGAP21 interactions through its C2
domain
b-Arrestin1 has previously been shown to bind the PTEN C2 domain directly and modulate PTEN
function (Lima-Fernandes et al., 2011). To investigate PTEN regulation of b-Arrestin1-ARHGAP21
interactions, we conducted co-immunoprecipitation (CoIP) studies and normalized b-Arrestin1-asso-
ciated ARHGAP21 against total ARHGAP21 densitometry values in cell lysates. Here, we show
greater b-Arrestin1-associated ARHGAP21 levels in PTEN-expressing Caco-2 or HCT116 cells versus
ShPTEN or PTEN-/- cells or IgG negative controls (Figure 3A,B). To investigate involvement of
PTEN catalytic and noncatalytic domains in these processes, we conducted transient expression
studies of GFP-labeled full-length wild type (wt) PTEN or mutants (Figure 3C), in PTEN-deficient
cells. Mutants included full-length PTEN with a mutation at the CBR3 membrane-binding loop within
the C2 domain (PTEN-MCBR3), full-length phosphatase-dead (PTEN C124S-based) constructs with
mutations in key C-terminal phosphorylation sites, namely PTEN C124S-T383A (CS-T383A) and
PTEN C124S-A4 (CS-A4 with S380A, T382A, T383A and S385A mutations combined). CS-T383A has
been proposed to contain an unmasked C2 domain (Raftopoulou et al., 2004) that effectively binds
b-Arrestin1 while CS-A4 lacks b-Arrestin1 binding capacity (Lima-Fernandes et al., 2011). We also
used the isolated PTEN C2 domain (C2) and a membrane-binding mutant of the C2 domain (C2-
MCBR3). We found that expression of C2 enhanced b-Arrestin1-associated ARHGAP21 levels in
CoIPs conducted in ShPTEN (Figure 3D,E,) and PTEN -/- cells (Figure 3—figure supplements 1 and
2). Conversely, C2-MCBR3 had no significant effect on b-Arrestin1-associated ARHGAP21 levels in
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Figure 2. PTEN controls morphogenesis through Cdc42/b-Arrestin1/ARHGAP21 interactions. (A,B) SiRNA b-Arrestin1 knockdown (KD) suppresses
Cdc42-GTP in Caco-2 and HCT116 cells (fold changes = 0.62 ± 0.09;*p=0.03 and 0.51 ± 0.03;**p=0.005 respectively. (C,D) SiRNA ARHGAP21 KD
enhances Cdc42-GTP in Caco-2 ShPTEN (ShPTEN) and HCT116 PTEN -/- (PTEN -/-) cells (fold change = 1.41 ± 0.09 and 1.51 ± 0.11, respectively; *p=0.02
for each. Cdc42-GTP ADU was normalized against total Cdc42. (E) SiRNA b-Arrestin1 KD suppresses Cdc42-GTP signal intensity, impairs spindle
Figure 2 continued on next page
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CoIPs (Figure 3D,E, Figure 3—figure supplements 1 and 2). b-Arrestin1-associated ARHGAP21 lev-
els were normalized against total ARHGAP21 expression in cell lysates. Collectively, these findings
indicate that the membrane-binding function of PTEN is important for scaffolding ARHGAP21 and b-
Arrestin1.
We then used an intramolecular bioluminescence resonance energy transfer (BRET)-based PTEN
biosensor (Lima-Fernandes et al., 2014; Misticone et al., 2016) to test if the full-length C124S C--
terminal phosphorylation mutants (Figure 3C) that have different b-Arrestin1 binding capacities
(Lima-Fernandes et al., 2011), display different conformations. The biosensor contains PTEN sand-
wiched between the energy donor Renilla luciferase (Rluc) and the energy acceptor YFP. Changes in
the BRET signal depend on the relative distance and orientation of the donor and acceptor proteins
within the fusion and therefore provide readout for conformational change of PTEN in live cells (Fig-
ure 3—figure supplement 3). Wild-type (wt) PTEN, CS-T383A and CS-A4 mutants in the Rluc-PTEN-
YFP construct produced different BRET signals (Figure 3—figure supplement 3). These findings
show that the phosphatase-dead mutants do indeed adopt different conformations, which is
Figure 2 continued
orientation and inhibits single lumen formation. High-power (HP) spindle views (orange border) enlarge areas within white rectangles and show
orientation angles (interrupted white arrows) of spindle planes (double-headed solid white arrows) toward gland centres (GCs). Normal spindle planes
are orientated at approximately 900 angles relative to gland centres [GCs] (Jaffe et al., 2008). Summary SiRNA effects on spindle angles relative to
GCs are shown in Figure 2—figure supplement 1. (F) Summary SiRNA effects on Cdc42-GTP intensity shown in (E) - control vs b-Arrestin1
SiRNA = 24.67 ± 1.45 vs 14.33 ± 0.88 AI units; **p=0.004. b-Arrestin1 KD also suppresses single central lumen formation in 3D Caco-2 cultures (E;
Figure 2—figure supplement 2). (G) SiRNA ARHGAP21 KD increases Cdc42-GTP signal intensity (H), rescues spindle orientation (G, Figure 2—figure
supplement 3) and central lumen formation in ShPTEN 3D cultures (G, Figure 2—figure supplement 4). (H) Cdc42-GTP, control vs SiRNA ARHGAP21
KD in ShPTEN cultures = 10.67 ± 0.67 vs=19.67 ± 0.88 AI units; **p<0.01. Assays at 4 days of culture. Imaging Cdc42-GTP [green], pericentrin (PCN)
[red], a-Tubulin [green], ARHGAP21 [red], PRKCZ [red], b-Arrestin1 [red] and DAPI [blue]. All experiments conducted in triplicate. All analyses by paired
Student’s t test. Scale bars 20 mm. Molecular weights indicated by arrows in blots.
DOI: https://doi.org/10.7554/eLife.24578.015
The following source data and figure supplements are available for figure 2:
Source data 1. Source data for Figure 2B.
DOI: https://doi.org/10.7554/eLife.24578.020
Source data 2. Source data for Figure 2D.
DOI: https://doi.org/10.7554/eLife.24578.021
Source data 3. Source data for Figure 2F.
DOI: https://doi.org/10.7554/eLife.24578.022
Source data 4. Source data for Figure 2H.
DOI: https://doi.org/10.7554/eLife.24578.023
Figure supplement 1. Summary effects of siRNA b-Arrestin1 or ARHGAP21 KD vs control non-targeting SiRNA on mitotic spindle angles and lumen
formation in 3D Caco-2 and Caco-2 ShPTEN (ShPTEN) cultures.
DOI: https://doi.org/10.7554/eLife.24578.016
Figure supplement 1—source data 1. Figure 2—figure supplement 1 Spindle angles in Caco-2 after Beta-Arrestin1 KD.
DOI: https://doi.org/10.7554/eLife.24578.024
Figure supplement 2. Summary effects of siRNA b-Arrestin1 or ARHGAP21 KD vs control non-targeting SiRNA on mitotic spindle angles and lumen
formation in 3D Caco-2 and Caco-2 ShPTEN (ShPTEN) cultures.
DOI: https://doi.org/10.7554/eLife.24578.017
Figure supplement 2—source data 1. Figure 2—figure supplement 2 - Single central lumen fomation on Caco-2 after Beta-Arrestin1 KD.
DOI: https://doi.org/10.7554/eLife.24578.025
Figure supplement 3. Summary effects of siRNA b-Arrestin1 or ARHGAP21 KD vs control non-targeting SiRNA on mitotic spindle angles and lumen
formation in 3D Caco-2 and Caco-2 ShPTEN (ShPTEN) cultures.
DOI: https://doi.org/10.7554/eLife.24578.018
Figure supplement 3—source data 1. Figure 2—figure supplement 3 Spindle angles in ShPTEN after ARHGAP21 KD.
DOI: https://doi.org/10.7554/eLife.24578.026
Figure supplement 4. Summary effects of siRNA b-Arrestin1 or ARHGAP21 KD vs control non-targeting SiRNA on mitotic spindle angles and lumen
formation in 3D Caco-2 and Caco-2 ShPTEN (ShPTEN) cultures.
DOI: https://doi.org/10.7554/eLife.24578.019
Figure supplement 4—source data 1. Figure 2—figure supplement 4 Single central lumen in ShPTEN after ARHGAP21kd.
DOI: https://doi.org/10.7554/eLife.24578.027
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Figure 3. PTEN C2 enhances b-Arrestin1-ARHGAP21 binding. (A) b-Arrestin1-ARHGAP21 CoIPs in PTEN-expressing and -deficient cells. b-Arrestin1-
associated ARHGAP21 shown in top panel against a constant b-Arrestin1 bait signal (second panel). IgG-negative controls. Total b-Arrestin1 and
ARHGAP21 in lysates and GAPDH loading controls shown in lower three panels. (B) Summary b-Arrestin1-associated ARHGAP21 in PTEN-deficient
(colored bars) vs PTEN-expressing cells (clear bars). Values normalized against total ARHGAP21 = 0.35 ± 0.01;**p<0.01 (ShPTEN) and 0.39 ± 0.02;
Figure 3 continued on next page
Javadi et al. eLife 2017;6:e24578. DOI: https://doi.org/10.7554/eLife.24578 8 of 29
Research article Cancer Biology Cell Biology
consistent with differences in b-Arrestin1-binding capacity. We further investigated protein-protein
interactions in vivo using sensitive proximity ligation assays [PLA] (So¨derberg et al., 2006). We
expressed PTEN phosphatase-dead mutants or C2 domain constructs in PTEN -/- cells. We found
prominent PLA signals for PTEN-b-Arrestin1 interactions in PTEN -/- cells expressing either PTEN CS-
T383A or the intact C2 domain. Conversely, PTEN-/- cells expressing PTEN CS-A4 or C2-MCBR3
mutants showed markedly reduced levels of these interaction signals. PTEN-b-Arrestin1 interaction
PLA signals in HCT116 and GFP-only transfected PTEN -/- cells were used as positive and negative
controls, respectively (Figure 3F; Figure 3—figure supplement 4). These findings indicate that
PTEN-b-Arrestin1 interactions can occur independently of PTEN phosphatase activity. Next, we
investigated effects of PTEN on b-Arrestin1-ARHGAP21 interactions. Transfection of PTEN -/- cells
with GFP-labeled-wt PTEN or -C2 domain enhanced b-Arrestin1-ARHGAP21 interactions compared
to cells transfected with PTEN-MCBR3 or C2-MCBR3. b-Arrestin1-ARHGAP21 interaction signals in
HCT116 or GFP-only transfected PTEN -/- cells were used as positive and negative controls, respec-
tively. (Figure 3G; Figure 3—figure supplement 5). Collectively, these data implicate the PTEN C2
domain in phosphatase-independent binding of b-Arrestin1 and in promoting b-Arrestin1-ARH-
GAP21 interactions.
Figure 3 continued
**p<0.01 (PTEN -/ - cells), respectively. (C) Schematic of GFP-labeled PTEN constructs used (top to bottom - wild type (wt) PTEN; PTEN - MCBR3
membrane binding mutant; catalytically inactive PTEN C124S; PTEN C124S - A4 (CS-A4) and PTEN C124S -T383A (CS-T383A) mutants that lack or retain
b-Arrestin1 binding capacity, respectively (Lima-Fernandes et al., 2011), C2 and the C2-MCBR3 membrane binding mutant. (D) b-Arrestin1-associated
ARHGAP21 in ShPTEN cells after transfection with GFP-labeled-EV control vs- C2 or -C2-MCBR3 (top panel). b-Arrestin1 bait signal shown in second
panel. Total b-Arrestin1 and ARHGAP21 in lysates shown in third and fourth panels. Expression of GFP-labeled C2, C2-MCBR3 and EV and GAPDH
loading controls shown in two lowest panels. (E) Summary fold change of b-Arrestin1-associated ARHGAP21 vs EV control; C2 = 2.51 ± 0.08;**p<0.01 or
C2-MBCR3 = 1.03 ± 0.06; p=NS. b-Arrestin1-associated ARHGAP21 normalized against total ARHGAP21 in lysate. (F) Proximity ligation assay (PLA) of b-
Arrestin1 interactions with PTEN constructs (red fluorescence) in PTEN -/- cells. Top row - GFP-labeled CS-T383A, CS-A4, C2, C2-MCBR3; Bottom row -
positive control - HCT116 cells; negative control - PTEN -/- cells transfected with GFP only. (G) b-Arrestin1-ARHGAP21 interactions. Top row PTEN -/-
cells transfected with GFP-labeled full-length PTEN, -PTEN-MCBR3, -C2 and -C2-MCBR3; Bottom row - positive control - HCT116 cells; negative control
- PTEN -/- cells transfected with GFP only. Scale bars - 20 mm; Molecular weights indicated by arrows in blots.
DOI: https://doi.org/10.7554/eLife.24578.028
The following source data and figure supplements are available for figure 3:
Source data 1. Source data for Figure 3B.
DOI: https://doi.org/10.7554/eLife.24578.034
Source data 2. Source data for Figure 3E.
DOI: https://doi.org/10.7554/eLife.24578.035
Figure supplement 1. Top panel - Effects of GFP-labelled empty vector (EV) control, C2 and C2-MCBR3-GFP on b-Arrestin1-associated ARHGAP21 in
PTEN -/- cells.
DOI: https://doi.org/10.7554/eLife.24578.029
Figure supplement 2. Fold changes of b-Arrestin1-associated ARHGAP21 shown in Figure 3—figure supplement 1 vs EV control.
DOI: https://doi.org/10.7554/eLife.24578.030
Figure supplement 2—source data 1. Figure 3—figure supplement 2 Transfection effects on Beta-Arrestin1-associated ARHGAP21
DOI: https://doi.org/10.7554/eLife.24578.036
Figure supplement 3. Diagram of Rluc-PTEN-YFP illustrating how conformational changes may alter BRET measurements, although the real
orientations of donor and acceptor proteins are not known.
DOI: https://doi.org/10.7554/eLife.24578.031
Figure supplement 4. PTEN:b-Arrestin1 interaction AI after transfection of PTEN -/- cells by CS-T383A, CS-A4, C2 or C2-MCBR3.
DOI: https://doi.org/10.7554/eLife.24578.032
Figure supplement 4—source data 1. Figure 3—figure supplement 4 PLA analysis of PTEN:Beta-Arrestin1 interactions.
DOI: https://doi.org/10.7554/eLife.24578.037
Figure supplement 5. b-Arrestin1-ARHGAP21 interaction AI after transfection of PTEN -/- cells by GFP-labelled C2, C2-MCBR3, wt PTEN or PTEN-
MCBR3.
DOI: https://doi.org/10.7554/eLife.24578.033
Figure supplement 5—source data 1. Figure 3—figure supplement 5 PLA assay of Beta-Arrestine1:ARHGAP21 interactions.
DOI: https://doi.org/10.7554/eLife.24578.038
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PTEN promotes b-Arrestin1 and ARHGAP21 membrane recruitment
through its C2 domain
To explore effects of the isolated PTEN C2 domain on membrane recruitment of b-Arrestin1 or ARH-
GAP21, we conducted expression, fractionation and CoIP assays in PTEN-deficient cells. Expression
of the C2 domain enhanced total b-Arrestin1 and suppressed that of ARHGAP21 in PTEN-deficient
cell lysates while C2-MCBR3 had no significant effects (Figure 4A–C; Figure 4—figure supplements
1–3). C2 expression also enriched b-Arrestin1 and suppressed ARHGAP21 in membrane fractions of
PTEN-deficient colorectal cell lines (Figure 4D–F; Figure 4—figure supplement 4). Membrane frac-
tion values were normalized against total expression of each protein in lysate. Furthermore, expres-
sion of C2 but not C2-MCBR3 also increased b-Arrestin1-associated ARHGAP21 levels in PTEN-
deficient cell membrane fractions. b-Arrestin1-associated ARHGAP21 levels were normalized against
total ARHGAP21 in the membrane fraction (Figure 4G–J). In PTEN -/- cells, expression of C2 and
full-length PTEN had greater effects on b-Arrestin1-associated ARHGAP21 levels than PTEN-
MCBR3, C2-MCBR3 or control (Figure 4I,J). PTEN-MCBR3 had small but significant effects on b-
Arrestin1-associated ARHGAP21 levels in excess of control (Figure 4I,J). Taken together, these data
indicate that PTEN enhances b-Arrestin1 membrane recruitment and b-Arrestin-ARHGAP21 interac-
tions, predominantly through its membrane-binding C2 domain.
PTEN controls mitotic spindle orientation and 3D morphogenesis by
regulation of b-Arrestin1
To investigate PTEN coordination of morphogenic processes through its C2 domain, we conducted
3D organotypic culture studies. We found greater expression and membrane localization of b-
Arrestin1 in 3D control PTEN-expressing Caco-2 cultures compared to ShPTEN cultures (Figure 5A,
Figure 5—figure supplement 1), in agreement with our biochemical analysis. Conversely, ARH-
GAP21 immunoreactivity was lower in control Caco-2 compared to ShPTEN 3D cultures (Figure 5B;
Figure 5—figure supplement 2). We have shown previously that the abnormal ShPTEN 3D pheno-
type can be rescued by expression of the PTEN C2 domain (Jagan et al., 2013b). Here, we show
that the GFP-tagged PTEN C2 domain enhances b-Arrestin1 membrane enrichment (Figure 5C,D),
rescues mitotic spindle orientation (Figure 5E,F) as well as apical membrane alignment and single
lumen morphology (Figure 5E; Figure 5—figure supplements 3 and 4) in 3D ShPTEN cultures.
These effects were not observed in ShPTEN cultures expressing control GFP or C2-MCBR3-GFP
(Figure 5C–F; Figure 5—figure supplements 3 and 4). To investigate any potential for PTEN
ShRNA off-target effects, we investigated effects of full-length ShRNA-resistant PTEN (ShR PTEN) on
the integrated ShPTEN 3D morphology phenotype. We show that expression of ShR PTEN rescued
defective morphogenesis of 3D ShPTEN cultures (Figure 5—figure supplements 5 and 6). Collec-
tively, these studies show that the membrane-bound PTEN C2 domain coordinates multicellular
gland assembly by b-Arrestin1 membrane recruitment, mitotic spindle orientation, apical membrane
alignment and lumen formation.
PTEN controls 3D Caco-2 morphogenesis by noncatalytic coupling of b-
Arrestin1, ARHGAP21 and Cdc42
Precise spatiotemporal coordination of Cdc42 activity is central to multicellular morphogenesis
(Meitinger et al., 2013). To investigate PTEN non-catalytic regulation of Cdc42 via b-Arrestin1 and
ARHGAP21, we conducted transfection and peptide inhibitor studies. Expression of the catalytically
inactive PTEN CS-T383A construct that binds b-Arrestin1 but not the PTEN CS-A4 binding-defective
mutant, enhanced Cdc42-GTP levels in PTEN -/- cells (Figure 6A,B). While Cdc42 can be inhibited by
ARHGAP21 (Dubois and Chavrier, 2005), competitive b-Arrestin1 binding to the GAP domain can
release the active GTPase from ARHGAP21 inhibition (Anthony et al., 2011). To investigate the spe-
cific role of b-Arrestin1-ARHGAP21 interactions on Cdc42-dependent 3D morphogenesis, we used a
cell-permeant 24-mer peptide analogue of the ARHGAP21 GAP domain that was designed to dis-
rupt the b-Arrestin1-ARHGAP21 interaction (Figure 6C) (Anthony et al., 2011). Here, we show that
treatment with this b-Arrestin1-ARHGAP21 peptide binding inhibitor (pep24) but not a scrambled
control peptide attenuated the association between b-Arrestin1 and ARHGAP21, resulting in lower
levels of b-Arrestin1-associated ARHGAP21 (Figure 6D,E; Figure 6—figure supplements 1 and
2). Treatment by pep24 also suppressed Cdc42 activation in Caco-2 (Figure 6F,G) and HCT116 cells
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Figure 4. PTEN regulation of juxtamembrane b-Arrestin1 and ARHGAP21. (A) shows total b-Arrestin1 and ARHGAP21 expression in Caco-2 ShPTEN cell
lysates (top two panels) after PTEN C2 (C2), C2-MCBR3 or EV control transfections. Expression levels of transfected GFP-labelled proteins and b-Actin
loading controls shown in lower two panels. (B) indicates summary fold changes of total b-Arrestin1; C2 = 1.23 ± 0.02; **p<0.01; MCBR3 = 1.07 ± 0.02;
[MCBR3 vs control = NS]. (C) shows respective fold changes of ARHGAP21; C2 = 0.8 ± 0.02; **p<0.01; MCBR3 = 0.95 ± 0.03; [MCBR3 vs control = NS;
Figure 4 continued on next page
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(Figure 6—figure supplements 3 and 4). Furthermore, pep24 treatment induced dysmorphogenesis
of 3D Caco-2 cultures characterized by mitotic spindle misorientation (Figure 6H, Figure 6—figure
supplement 5), apical membrane misalignment, aberrant epithelial configuration and loss of single
central lumen formation (Figure 6I, Figure 6—figure supplement 6). Taken together, these data
show that PTEN controls 3D morphogenesis by non-catalytic C2 domain scaffolding of b-Arrestin1-
ARHGAP21 interactions and release of Cdc42 from ARHGAP21 inhibition.
Figure 4 continued
all values in ADU]. (D) Effects of transfections on cytosol and membrane b-Arrestin1 and ARHGAP21 in Caco-2 ShPTEN (ShPTEN) cells (top two panels).
Expression levels of transfected GFP-labelled proteins and E-Cadherin and HSP90 membrane and cytosolic markers shown in lower three panels. (E, F)
Fold change of b-Arrestin1 and ARHGAP21 expression induced in the membrane fraction. (E) b-Arrestin1, C2 = 1.25 ± 0.05; *p=0.04 and (F)
ARHGAP21 = 0.53 ± 0.09; *p=0.03. b-Arrestin1 and ARHGAP21 ADU values normalized against total lysate ADU for each protein. (G) b-Arrestin1-
associated ARHGAP21 induced in ShPTEN membrane fractions by C2, C2-MCBR3 vs EV control transfections (top panel). b-Arrestin1 bait signal shown
in second panel. Total b-Arrestin1 and ARHGAP21 in lysates shown in third and fourth panels. Expression of GFP-labeled C2, C2-MCBR3, EV and
E-Cadherin membrane marker shown in lower three panels. (H) Fold changes of b-Arrestin1-associated ARHGAP21 normalized against total ARHGAP21
in the membrane fraction (ADU) - C2 = 6.27 ± 0.51; ***p<0.001; MCBR3 = 1.25 ± 0.15; [MCBR3 vs control = NS]. (I) b-Arrestin1-associated ARHGAP21
ADU after expression of C2, C2-MCBR3, wt PTEN or PTEN-MCBR3 vs EV control in PTEN -/- cell membrane fractions (top panel). b-Arrestin1 bait signal,
total lysate expression of each protein, expression of GFP-labelled EV or C2 domain constructs and E-Cadherin membrane marker shown in lower five
panels. (J) Summary fold changes of b-Arrestin1-associated ARHGAP21 normalized against total membrane ARHGAP21; C2 = 7.33 ± 0.64; C2-
MCBR3 = 2.5 ± 0.35; PTEN = 12.93 ± 0.19; PTEN MCBR3 = 3.15 ± 0.21 ADU; control vs C2 or PTEN, ***p<0.001; control vs C2-MCBR3 (NS). Control vs
PTEN-MCBR3 = *p<0.05. Analyses by ANOVA, Tukey post hoc or Student’s paired test. Molecular weights indicated by arrows in blots.
DOI: https://doi.org/10.7554/eLife.24578.039
The following source data and figure supplements are available for figure 4:
Source data 1. Source data for Figure 4B.
DOI: https://doi.org/10.7554/eLife.24578.046
Source data 2. Source data for Figure 4C.
DOI: https://doi.org/10.7554/eLife.24578.047
Source data 3. Source data for Figure 4E.
DOI: https://doi.org/10.7554/eLife.24578.048
Source data 4. Source data for Figure 4F.
DOI: https://doi.org/10.7554/eLife.24578.049
Source data 5. Source data for Figure 4H.
DOI: https://doi.org/10.7554/eLife.24578.050
Source data 6. Source data for Figure 4J.
DOI: https://doi.org/10.7554/eLife.24578.051
Figure supplement 1. Total b-Arrestin1 and ARHGAP21 expression (top two panels) in.
DOI: https://doi.org/10.7554/eLife.24578.040
Figure supplement 2. Fold changes of b-Arrestin1 - C2 = 1.24 ± 0.03; *p<0.05; C2-MCBR3 = 1.11 ± 0.06 [MCBR3 vs control = NS].
DOI: https://doi.org/10.7554/eLife.24578.041
Figure supplement 2—source data 1. Figure 4—figure supplement 2 Transfection effects on Beta-Arrestin1 in PTEN-/- cells.
DOI: https://doi.org/10.7554/eLife.24578.052
Figure supplement 3. Fold changes of ARHGAP21.
DOI: https://doi.org/10.7554/eLife.24578.042
Figure supplement 3—source data 1. Figure 4—figure supplement 3 Transfection effects on ARHGAP21 in PTEN-/- HCT116 cells.
DOI: https://doi.org/10.7554/eLife.24578.053
Figure supplement 4. Fold changes of membrane ARHGAP21 (0.82 ± 0.03;**p<0.01).
DOI: https://doi.org/10.7554/eLife.24578.043
Figure supplement 5. Effects of transfection on cytosol and membrane b-Arrestin1 and ARHGAP21 in PTEN -/- cells (top two panels).
DOI: https://doi.org/10.7554/eLife.24578.044
Figure supplement 5—source data 1. Figure 4—figure supplement 5 Membrane Beta-Arrestin1 in PTEN-/- cells - Source data.
DOI: https://doi.org/10.7554/eLife.24578.054
Figure supplement 6. Fold changes of membrane b-Arrestin1 (1.16 ± 0.03; *p=0.04).
DOI: https://doi.org/10.7554/eLife.24578.045
Figure supplement 6—source data 1. Figure 4—figure supplement 6 - Transfection effects on Membrane ARHGAP21in PTEN-/- cells.
DOI: https://doi.org/10.7554/eLife.24578.055
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Figure 5. PTEN controls mitotic spindle orientation and 3D morphogenesis by noncatalytic regulation of b-Arrestin1. (A) b-Arrestin1 and (B) ARHGAP21
immunofluorescence intensity in 3D control Caco-2 and ShPTEN cultures. (C) Effects of C2 vs C2-MCBR3 expression on membrane b-Arrestin1
immunoreactivity in ShPTEN cultures. (D) Summary cell membrane b-Arrestin1 immunoreactivity AI; EV control vs C2 vs C2-MCBR3 = 9.0 ± 2.08 vs
23.3 ± 1.20 vs 6.33 ± 1.67 AI;**p<0.01, control vs C2-MCBR3 = NS. (E) Effects of C2 vs C2-MCBR3 expression on spindle orientation. High-power (HP)
Figure 5 continued on next page
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b-Arrestin1-ARHGAP21 interactions are essential for self-assembly of
normal colorectal organoids
To avoid any compromise of experimental interpretation by intrinsic Caco-2 cancer cell mutations,
we investigated our key observations from cell culture experiments in organoids formed from pri-
mary normal murine colon cells (Clevers, 2016). In this study, we cultured colonic crypt progenitor
epithelium in Matrigel supplemented with growth factors as previously described (Sato et al.,
2011). By these methods, we generated colorectal organoids with appropriate mitotic spindle orien-
tation, apical membrane alignment, luminogenesis and epithelial organization, in 3D cultures
(Figure 7A–C). To investigate the role of b-Arrestin1-ARHGAP21 interactions on colorectal homeo-
stasis, we assessed effects of pep24 vs control peptide treatment on 3D organoid morphogenesis.
Here, we show that pep24 treatment perturbed mitotic spindle orientation, disrupted 3D glandular
morphology and lumen formation in normal colorectal organoids (Figure 7A–C). Conversely, control
peptide treatment had no discernible effect on 3D glandular morphology (Figure 7A–C). Collec-
tively, these findings highlight a significant role for b-Arrestin1-ARHGAP21 interaction in multicellular
morphogenesis of normal colorectal epithelium.
Discussion
Scaffolding proteins have unique properties for assembling target molecules into cooperative net-
works within subcellular compartments (Rock et al., 2013) to control diverse biological functions
Figure 5 continued
spindle views (orange border) enlarge areas within white rectangles and show orientation angles (interrupted white arrows) of spindle planes (double-
headed solid white arrows) toward gland centres (GCs). (F) Summary spindle angles relative to GCs in 3D ShPTEN cultures after transfection (. –
Control = 32.08 ± 5.50 vs . - C2 = 65.72 ± 4.10; **p<0.01 vs . - MCBR3 = 29.1 ± 4.40; [MCBR3 vs control = NS], One-way ANOVA; **p<0.01, Tukey post
hoc test. Imaging - DAPI [blue], b-Arrestin1 (A,C) red, ARHGAP21, (B) [red], GFP [green] and a-Tubulin (E) [cyan]. Scale bars = 20 mm.
DOI: https://doi.org/10.7554/eLife.24578.056
The following source data and figure supplements are available for figure 5:
Source data 1. Source data for Figure 5D.
DOI: https://doi.org/10.7554/eLife.24578.063
Source data 2. Source data for Figure 5F.
DOI: https://doi.org/10.7554/eLife.24578.064
Figure supplement 1. Summary b-Arrestin1 immunoreactivity (AI) in control Caco-2 vs ShPTEN organotypic cultures in Figure 5A = 24.3 ± 4.1 vs
11.00 ± 1.16;*p=0.04.
DOI: https://doi.org/10.7554/eLife.24578.057
Figure supplement 1—source data 1. Figure 5—figure supplement 1 - Beta-Arrestin 1 intensity in Caco-2 and ShPTEN.
DOI: https://doi.org/10.7554/eLife.24578.065
Figure supplement 2. ARHGAP21 immunoreactivity (AI) in control Caco-2 vs ShPTEN organotypic cultures in Figure 5B = 8.0 ± 0.58 vs 17.0 ± 2.64 AI;
*p=0.02.
DOI: https://doi.org/10.7554/eLife.24578.058
Figure supplement 2—source data 1. Figure 5—figure supplement 2 ARHGAP21 intensity in Caco-2 and ShPTEN glands.
DOI: https://doi.org/10.7554/eLife.24578.066
Figure supplement 3. Effects of expression C2 or C2-MCBR3 vs EV control on lumen formation in ShPTEN cultures.
DOI: https://doi.org/10.7554/eLife.24578.059
Figure supplement 4. Effects of expression C2 or C2-MCBR3 vs EV control on lumen formation in ShPTEN cultures.
DOI: https://doi.org/10.7554/eLife.24578.060
Figure supplement 4—source data 1. Figure 5—figure supplement 4 Transfection effects on single lumen formation in ShPTEN.
DOI: https://doi.org/10.7554/eLife.24578.067
Figure supplement 5. Effects of ShRNA-resistant (shR) PTEN or EV control on lumen formation in ShPTEN cultures.
DOI: https://doi.org/10.7554/eLife.24578.061
Figure supplement 6. Summary effects of shR PTEN vs EV control on single lumen formation in 3D ShPTEN cultures - control = 11.33 ± 2.40%; ShR
PTEN = 30.67 ± 2.91%; **p<0.01.
DOI: https://doi.org/10.7554/eLife.24578.062
Figure supplement 6—source data 1. Figure 5—figure supplement 6 Effects of shRNA resistant PTEN on single lumen formation in ShPTEN glands.
DOI: https://doi.org/10.7554/eLife.24578.068
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Figure 6. PTEN morphogenic functions mediated by b-Arrestin1, ARHGAP21 and Cdc42. (A) Effects of PTEN CS-A4 or PTEN CS-T383A vs EV control
on Cdc42 - GTP levels in PTEN -/- cells. (B) indicates fold change of Cdc42-GTP vs EV control; CS-A4 = 0.92 ± 0.16;p=NS; CS-T383A = 1.64 ± 0.11;
**p=0.008. (C) Schematic of ARHGAP21 showing the b-Arrestin1-binding domain, the pep24 peptide-binding inhibitor and control peptide sequences
(Anthony et al., 2011). Effects of pep24 vs control peptide (pep) on b-Arrestin1-ARHGAP21 binding (D,E) and Cdc42-GTP (F,G) in Caco-2 cells. (E)
Figure 6 continued on next page
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(Oh and Schnitzer, 2001; Eroglu et al., 2003; Irazoqui et al., 2003; Smith and Scott, 2013). b-
Arrestin1 acts as a molecular scaffold for G-protein-coupled receptors [GPCRs] (Luttrell et al.,
1999), the largest family of signaling receptors. Key GPCRs enhance b-Arrestin1 recruitment to the
plasma membrane (Urs et al., 2005; Li et al., 2009; De´caillot et al., 2011), activate PTEN
(Song et al., 2009; Sanchez et al., 2005) and promote PTEN-b-Arrestin1 interactions (Lima-
Fernandes et al., 2011). b-Arrestin1 also suppresses ARHGAP21 (Anthony et al., 2011) that is inde-
pendently recruited to the plasma membrane by ADP-ribosylation factor 1 [ARF-1] (Kumari and
Mayor, 2008). In this study, we investigated PTEN coregulation of b-Arrestin1 and ARHGAP21. We
found greater b-Arrestin1 levels in lysates of PTEN-expressing HCT116 cells than in the isogenic
PTEN-null (PTEN -/-) subclone and near-significant differences in corresponding PTEN-expressing
and -deficient Caco-2 cells. While the precise mechanisms of this effect remain unclear, PTEN muta-
tion or deficiency and changes in b-Arrestin1 expression levels characterize various human cancers
(Cantley and Neel, 1999; Enslen et al., 2014).
As well as protein abundance, stoichiometry and post-translational targeting machinery modulate
the assembly of spatially restricted scaffolding complexes (Boisvert et al., 2012). LPAR is a lyso-
phosphatidic acid (LPA) activated GPCR that couples heterotrimeric G proteins, to control mem-
brane recruitment of b-Arrestin1 (Urs et al., 2005; Li et al., 2009), GTPase activity (Ueda et al.,
Figure 6 continued
indicates fold change of b-Arrestin1-associated ARHGAP21 ADU in Caco-2 cells after pep24 vs control peptide treatment = 0.63 ± 0.02; **p=0.003. (G)
indicates fold change of Cdc42-GTP in Caco-2 cells after pep24 vs control peptide treatment = 0.48 ± 0.05; **p=0.01. Treatment effects on spindle
orientation (H) and lumenogenesis (I) in 3D Caco-2 cultures. Imaging for pericentrin (PCN) [red]; PRKCZ [red]; a-Tubulin [green], DAPI for nuclear DNA
[blue] and bright-field (BF) imaging of lumen outlines. Spindle planes indicated by double-headed white arrows in Merge (H). Analyses by ANOVA,
Tukey’s post hoc test. Scale bar - 20 mm. Molecular weights indicated by arrows in blots.
DOI: https://doi.org/10.7554/eLife.24578.069
The following source data and figure supplements are available for figure 6:
Source data 1. . Figure 6B -Cdc42-GTP after transfection - source data
DOI: https://doi.org/10.7554/eLife.24578.076
Source data 2. Figure 6E - Peptide inhibitor treatment effects on Beta Arrestin1:ARHGAP21 binding in Caco-2
DOI: https://doi.org/10.7554/eLife.24578.077
Source data 3. Figure 6G Peptide inhibitor treatment effects on Cdc42-GTP in Caco-2
DOI: https://doi.org/10.7554/eLife.24578.078
Figure supplement 1. pep24 vs control peptide treatment effects on b-Arrestin1-associated ARHGAP21 ADU = 0.39 ± 0.09;*p=0.02.
DOI: https://doi.org/10.7554/eLife.24578.070
Figure supplement 2. pep24 vs control peptide treatment effects on b-Arrestin1-associated ARHGAP21 ADU = 0.39 ± 0.09;*p=0.02.
DOI: https://doi.org/10.7554/eLife.24578.071
Figure supplement 2—source data 1. Figure 6—figure supplement 2 Effects of peptide binding inhibitor on Beta-arrestin1:ARHGAP21 interactions
in HCT116 cells
DOI: https://doi.org/10.7554/eLife.24578.079
Figure supplement 3. pep24 vs control peptide treatment effects on Cdc42-GTP ADU = 0.44 ± 0.02; **p<0.01 in HCT116 cells.
DOI: https://doi.org/10.7554/eLife.24578.072
Figure supplement 4. pep24 vs control peptide treatment effects on Cdc42-GTP ADU = 0.44 ± 0.02; **p<0.01 in HCT116 cells.
DOI: https://doi.org/10.7554/eLife.24578.073
Figure supplement 4—source data 1. Figure 6—figure supplement 4 - Peptide inhibitor treatment effects in Cdc42-GTP in HCT116 cells - source
data
DOI: https://doi.org/10.7554/eLife.24578.080
Figure supplement 5. Summary treatment effects on mitotic spindle angles [.Control peptide = 67.4 ± 5.50 vs . pep24 = 28.1 ± 5.10; ***p<0.001] and %
glands with single central lumens in 3D Caco-2 cultures (Control peptide = 35.33 ± 1.76% vs pep24 = 20.67 ± 1.76%;**p<0.01).
DOI: https://doi.org/10.7554/eLife.24578.074
Figure supplement 5—source data 1. Figure 6—figure supplement 5 - Peptide inhibitor treatment effects on spindle angles in Caco-2 cultures
DOI: https://doi.org/10.7554/eLife.24578.081
Figure supplement 6. Summary treatment effects on mitotic spindle angles [.Control peptide = 67.4 ± 5.50 vs . pep24 = 28.1 ± 5.10; ***p<0.001] and %
glands with single central lumens in 3D Caco-2 cultures (Control peptide = 35.33 ± 1.76% vs pep24 = 20.67 ± 1.76%;**p<0.01).
DOI: https://doi.org/10.7554/eLife.24578.075
Figure supplement 6—source data 1. Figure 6—figure supplement 6 Peptide inhibitor treatment effects on spindle angles in Caco-2 cultures
DOI: https://doi.org/10.7554/eLife.24578.082
Javadi et al. eLife 2017;6:e24578. DOI: https://doi.org/10.7554/eLife.24578 16 of 29
Research article Cancer Biology Cell Biology
Figure 7. b-Arrestin1-ARHGAP21 binding is essential for morphogenesis of normal colorectal organoids. (A) Effects of pep24 vs control peptide (pep)
on multicellular morphogenesis of normal colorectal epithelium. Imaging - apical actin marker FITC-labeled phalloidin [green], DAPI for nuclear DNA
[blue] and FITC-labeled a-Tubulin [green]. Spindle orientation indicated by double-headed white arrows. (B) Summary spindle angles in 3D colorectal
organoids after treatment (n = 30 per treatment group) .Control peptide = 68.47 ± 5.370 vs .pep24 = 31.13 ± 3.200; ***p<0.001. (C) Summary data
Figure 7 continued on next page
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2001) and cell polarization processes (Nagasaki and Gundersen, 1996). To investigate these phe-
nomena, we assessed spontaneous and LPA-mediated cell membrane localization of b-Arrestin1 and
ARHGAP21 in subcellular fractions of PTEN-expressing and -deficient cells. We found proportion-
ately greater differences of constitutive and LPA-mediated b-Arrestin1 membrane localization in
PTEN-expressing Caco-2 vs PTEN-deficient ShPTEN cells, indicative of PTEN involvement in b-
Arrestin1 membrane recruitment. Similarly, LPA promoted greater b-Arrestin1 membrane localiza-
tion in PTEN-expressing HCT116 cells than in PTEN -/- cells. In both cell types, we found reciprocal
differences of ARHGAP21 membrane localization, consistent with b-Arrestin1-mediated suppression
(Anthony et al., 2011). To investigate PTEN effects on b-Arrestin1 plasma membrane recruitment in
whole cells, we used confocal microscopy to track the spatial distribution of transfected b-Arrestin1-
mCherry against plasma membrane localization of Alexa 488-labeled WGA. Line scans of fluores-
cence intensities across image focal planes and high-resolution confocal z-stack reconstructions
(Furia et al., 2014) revealed that PTEN enhanced LPA-mediated b-Arrestin1-mCherry colocalization
with Alexa 488 -labelled WGA at the plasma membrane. LPA treatment had limited effects on b-
Arrestin1-mCherry plasma membrane recruitment in ShPTEN cells that have residual low level PTEN
but was ineffective in PTEN -/- cells. We cannot attribute these findings to nonspecific fluorophore
diffusion, since mCherry distribution was unaffected by PTEN status or LPA treatment. Furthermore,
we can exclude PTEN nonspecific effects on cell membrane protein localization because 1,25
(OH)2D3-induced plasma membrane recruitment of E-Cadherin (Pa´lmer et al., 2001) was equivalent
in PTEN-expressing and -deficient cells. Collectively, these findings show that PTEN is an essential
coregulator of plasma membrane recruitment of b-Arrestin1 and of b-Arrestin1:ARHGAP21 func-
tional interactions.
b-Arrestin1 and ARHGAP21 coregulate GTPases (Anthony et al., 2011) that function as a signal-
ing hub for diverse cytokinetic processes (Glover et al., 2008; Jaffe et al., 2008). We investigated
PTEN regulation of GTPase activity through b-Arrestin1-ARHGAP21 scaffolding and conducted per-
turbation experiments in organotypic 3D culture models that are ideal for precise, image-based
assays of multiscale epithelial homeostasis. We found that siRNA knockdown (KD) of b-Arrestin1 sup-
pressed Cdc42 activation in PTEN-expressing cells and 3D cultures while siRNA ARHGAP21 KD had
reciprocal effects by increasing Cdc42 activity in PTEN-deficient cultures. Furthermore, these pertur-
bation experiments affected sequential layers of homeostatic controls. Suppression of b-Arrestin1
induced mitotic spindle misorientation, abnormal epithelial configuration, defective apical mem-
brane positioning and formation of multiple lumens during assembly of PTEN-expressing 3D Caco-2
glandular structures. Conversely, ARHGAP21 KD increased Cdc42 activation, restored spindle orien-
tation and rescued aberrant morphogenesis of isogenic PTEN-deficient 3D ShPTEN cultures.
Because of the previously reported relationship between ARHGAP21 and RhoA (Lima-
Fernandes et al., 2011), we assessed relationships between PTEN, b-Arrestin1, ARHGAP21 and
RhoA. PTEN KD suppressed b-Arrestin1, enhanced ARHGAP21 and suppressed RhoA activation.
Collectively, these findings indicate that PTEN orchestrates the cell division plane and apical mem-
brane dynamics during multicellular morphogenesis by coordination of b-Arrestin1-ARHGAP21 func-
tional interactions and GTPase activity.
In accord with the above findings, we found that PTEN enhanced b-Arrestin1-ARHGAP21 interac-
tions. PTEN interacts with b-Arrestin1 (Lima-Fernandes et al., 2011), localizes to the plasma mem-
brane (Lee et al., 1999) and modulates multicellular morphogenesis (Jagan et al., 2013b) via its C2
domain. Conversely, PTEN C2 domain mutations perturb multicellular patterning during
Figure 7 continued
represent percentage glandular colorectal organoids with single central lumens after treatment; control peptide = 80.00 ± 5.77% vs
pep24 = 36.67 ± 3.3%;*p=0.039; (n = 10 organoids per treatment group in triplicate). Student’s t test. Scale bar 20 mm.
DOI: https://doi.org/10.7554/eLife.24578.083
The following source data is available for figure 7:
Source data 1. Figure 7B Spindle angles in organoids - souce data.
DOI: https://doi.org/10.7554/eLife.24578.084
Source data 2. Figure 7C Single central lumen formation in organoids - source data.
DOI: https://doi.org/10.7554/eLife.24578.085
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development and neoplastic progression (Caserta et al., 2015) by unclear mechanisms. C2 domain
molecular interactions are masked by a closed PTEN intramolecular conformation (Rahdar et al.,
2009). However, studies of the isolated C2 domain or an unmasked C2 mediated by alanine substi-
tution at T383 [T383A] (Raftopoulou et al., 2004) within a PTEN C124S mutant construct, enables
study of PTEN-phosphatase independent C2 domain molecular interactions. A C124S A4 mutant
containing alanine substitutions at Ser380, Thr382, Thr383 and Ser385 suppresses b-Arrestin1 binding
(Lima-Fernandes et al., 2011). We used these constructs together with appropriate tools for detec-
tion of protein binding or conformational change to investigate scaffolding functions. We found in
CoIP studies that the isolated PTEN C2 domain enhanced b-Arrestin1-associated ARHGAP21
expression in excess of that induced by the C2-MCBR3 membrane-binding mutant. Bioluminescence
energy transfer (BRET) analysis of Rluc-PTEN-YFP biosensor constructs containing PTEN CS-T383A
or PTEN-CS-A4 (35) revealed different conformational dynamics consistent with differential protein
binding. Proximity ligation assay (PLA) is a sensitive method for visualization of signals generated by
protein-protein interactions (So¨derberg et al., 2006). We found strong interactions between
unmasked or isolated PTEN C2 domains and b-Arrestin1, in excess of that observed with the C2-
MCBR3 or C124S A4 mutants. Furthermore, expression of wt PTEN or the C2 domain in PTEN -/-
HCT116 cells enhanced b-Arrestin1-ARHGAP21 interaction signals, in excess of PTEN-MCBR3 (full-
length PTEN mutated at the CBR3-membrane-binding loop) or C2-MCBR3. Interestingly, the PTEN-
MCBR3 mutant had some limited scaffolding function, indicated by increased b-Arrestin1-ARH-
GAP21 binding in excess of control or C2-MCBR3 in PLA assays. Notwithstanding this finding, our
data indicate that PTEN binds b-Arrestin1 and promotes b-Arrestin1-ARHGAP21 interactions pre-
dominantly through its intact C2 domain.
C2 domains are phospholipid and protein binding modules involved in membrane recruitment
and localization of signaling molecules (Corbala´n-Garcı´a and Go´mez-Ferna´ndez, 2010). Here, we
show that PTEN C2 enhances b-Arrestin1 expression. While precise mechanisms remain unclear,
PTEN C2 binds thioredoxin-1 (Meuillet et al., 2004) that regulates b-Arrestin1 in a context-depen-
dent manner (Jia et al., 2014). In this study, PTEN C2 also promoted membrane enrichment of b-
Arrestin1 in excess of total lysate concentrations and enhanced b-Arrestin1-ARHGAP21 interactions.
Interestingly, wt PTEN promoted greater b-Arrestin1-associated ARHGAP21 expression in mem-
brane fractions than the isolated C2 domain. Within its N-terminal domain, full-length PTEN contains
a conserved polybasic phosphatidylinositol[4,5] biphosphate (PtdIns [4,5P2]) [PIP2]-binding site that
participates in membrane-targeting (Walker et al., 2004) and could complement PTEN C2 domain-
mediated interactions between scaffold complexes and membrane lipids. Similarly, in CoIP assays
PTEN-MCBR3 promoted a small but significant increase of b-Arrestin1-associated ARHGAP21
expression in excess of C2-MCBR3. Taken together, our findings indicate that PTEN promotes b-
Arrestin1-ARHGAP21 interactions predominantly through its C2 domain, although the PTEN N--
terminal domain has a weak additional effect.
PTEN, b-Arrestins and GTPase-activating proteins modulate the activity of Rho GTPases CdcC42
and RhoA (Martin-Belmonte et al., 2007; Anthony et al., 2011; Bos et al., 2007; Anderson et al.,
2008). Furthermore, the PTEN C2 domain has morphogenic properties (Leslie et al., 2007;
Jagan et al., 2013b; Caserta et al., 2015). We investigated PTEN orchestration of multicellular
gland assembly through its C2 domain, in organotypic culture studies. We found greater b-Arrestin1
and lower ARHGAP21 immunoreactivity in control Caco-2 vs ShPTEN 3D cultures in accord with our
findings in cell monolayers. Transfection of ShPTEN cells with a C2 domain construct promoted b-
Arrestin1 membrane localization, rescued mitotic spindle orientation, single central lumen formation
and 3D multicellular morphogenesis. Conversely, expression of the membrane-binding mutant C2-
MCBR3 domain did not rescue the morphology phenotype. ShPTEN cells stably express PTEN
ShRNA that targets the phosphatase domain (Jagan et al., 2013a). To assess PTEN ShRNA specific-
ity and test for potential off-target effects, we investigated effects of full-length ShRNA-resistant
PTEN (ShR PTEN) on the integrated ShPTEN 3D morphology phenotype. Expression of ShR PTEN
rescued 3D ShPTEN morphogenesis and thus confirmed shRNA functional specificity. Collectively,
the above data show that PTEN has important noncatalytic morphogenic functions mediated
through its C2 domain and b-Arrestin1 membrane targeting.
To investigate Cdc42 activation by the unmasked PTEN C2 domain, we conducted expression
studies in PTEN -/- cells. Transfection of PTEN CS-T383A robustly enhanced Cdc42-GTP, while the b-
Arrestin1-binding defective CS-A4 mutant (Lima-Fernandes et al., 2011) had no effect. Subsequent
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to these Cdc42 activation studies, we investigated the specific role of b-Arrestin1-ARHGAP21 inter-
actions on Cdc42-dependent multicellular morphogenesis. We used a cell-permeant peptide ana-
logue of the b-Arrestin1 docking site within the ARHGAP21 GAP domain (pep24) to disrupt b-
Arrestin-ARHGAP21 interactions (Anthony et al., 2011). Pep24 treatment suppressed b-Arrestin1-
associated ARHGAP21 expression, inhibited Cdc42 activation, induced spindle misalignment and
aberrant morphogenesis of 3D Caco-2 cultures. These morphogenic effects phenocopied those of
Cdc42 knockdown (Jagan et al., 2013a; Jaffe et al., 2008). Collectively, our findings indicate that
PTEN C2 coordinates b-Arrestin1-ARHGAP21 and Cdc42-dependent multicellular morphogenesis in
a 3D colorectal cancer model system.
PTEN is frequently downregulated in human colorectal (Naguib et al., 2011) and other cancers,
even in the absence of genetic loss or mutation (Salmena et al., 2008). Regulatory cues may have a
central role in tumorigenesis (Song et al., 2012). Activated GPCRs modulate b-Arrestin1 conforma-
tion (Shukla et al., 2008), membrane recruitment (Urs et al., 2005; Li et al., 2009; De´caillot et al.,
2011) and PTEN-b-Arrestin1 interactions (Lima-Fernandes et al., 2011). By these processes, GPCRs
may influence b-Arrestin1-dependent GTPase activation, cytoskeletal dynamics and neoplastic multi-
cellular patterning. Studies in cancer cell models provide useful mechanistic data (Hanahan and
Weinberg, 2011) but intrinsic mutations may compromise physiological relevance. Studies of 3D
multicellular organoids isolated from normal tissues have provided basic insights into normal tissue
morphogenesis (Clevers, 2016). We have previously generated intestinal crypt organoids for study
of multicellular assembly, patterning and lineage commitment (Campbell et al., 1993; Tait et al.,
1994; Slorach et al., 1999). Suppression of b-Arrestin1-ARHGAP21 binding in organoid systems by
pep24 treatment perturbed spindle orientation and apical membrane alignment to induce a multilu-
men phenotype, surrounded by disorganized epithelium. Collectively, these findings demonstrate
the importance of b-Arrestin1-ARHGAP21 interactions in control of normal colorectal multicellular
architecture.
Within the PTEN C2 domain, the CBR3 loop can localize cytoplasmic PTEN to early endosomes
arranged along the microtubule cytoskeleton, by binding endosomal PIP3 (Naguib et al., 2015).
Restriction of PTEN to a punctate vesicular distribution along microtubules may enable dephosphor-
ylation of PIP3 signals generated by plasma membrane receptor tyrosine kinases and parcelled in
endosomes (Naguib et al., 2015). However, it is difficult to envisage that wide endosomal distribu-
tion of scaffolding interactions along the microtubule cytoskeleton could regulate the compartmen-
talized focus of GTPase activity (Pertz, 2010) required for control of spindle dynamics and
multicellular morphogenesis (Durgan et al., 2011). Hence, dephosphorylation of PIP3 on endosomes
and scaffolding of b-Arrestin1-ARHGAP21 may represent spatiotemporally distinct PTEN tumor sup-
pressor functions.
This study shows that b-Arrestin1-ARHGAP21 interactions represent an essential component of
the PTEN morphogenic pathway and sheds light on conserved developmental mechanisms. In C.
elegans, PTEN/DAF18 conducts nutrient-sensing through its phosphatase domain (Ogg and Ruv-
kun, 1998) in a negative feedback loop with the insulin/IGF axis (Narbonne et al., 2015) and casein
kinase II [CKII] (Liu Tj et al., 2001). CKII phosphorylates PTEN to induce the closed conformation
(Rahdar et al., 2009; Torres and Pulido, 2001) that suppresses plasma membrane binding
(Rahdar et al., 2009). We show that the PTEN membrane-binding C2 domain is essential for multi-
cellular morphogenesis. Hence, our findings may provide a rationale for PTEN multifaceted control
of embryonic development by nutrient-sensing (Ogg and Ruvkun, 1998) and regulation of morpho-
genic growth (Rouault et al., 1999) according to the available nutrient energy balance
(Hietakangas and Cohen, 2009). Our study also has oncological relevance, since disruption of PTEN
C2 domain-mediated b-Arrestin1-ARHGAP21 interactions drive evolution of morphology pheno-
types in 3D cultures that are evocative of colorectal cancer (Deevi et al., 2016; Jaffe et al., 2008).
Dissection of these phenomena may yield novel targets for therapy aimed at suppression of aggres-
sive cancer morphology phenotypes that predict early metastasis.
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Materials and methods
Reagents and antibodies
All laboratory chemicals were purchased from Sigma-Aldrich, Dorset, England unless otherwise
stated. RNAiMAX and X-tremeGENE transfection reagents were purchased from Thermofisher, Dub-
lin, Ireland and Roche, Basel, Switzerland, respectively. Antibodies used in this study were anti-b-
Actin (A5316; Sigma Aldrich, Dorset, England [RRID:AB_476743]); anti-b-Arrestin1 (ab32099; Abcam,
Cambridge, UK [RRID:AB_722896]); anti-ARHGAP21 (55139-1-AP; Proteintech Manchester, UK
[RRID:AB_10794449]); anti-E-Cadherin (562526; BD Biosciences, Oxford, UK [RRID:AB_11153868]);
anti-GAPDH (ab8245; Abcam, Cambridge, UK [RRID:AB_2107448]); anti-GFP (ab8245; Abcam, Cam-
bridge, UK [RRID:AB_298911 ]); anti-HSP90 (sc-7947; Santa Cruz, Dallas, Texas, USA [RRID:AB_
2121235]); anti-Pericentrin (PCN:ab4448; Abcam, Cambridge, UK [RRID:AB_304461]); anti-Protein
Kinase C z [PRKCZ] (ab51157; Abcam, Cambridge, UK [RRID:AB_882057]); anti-PTEN (ab32199;
Abcam, Cambridge, UK [RRID:AB_777535]); anti-a-Tubulin (Ab7291; Abcam, Cambridge, UK [RRID:
AB_2241126]); anti-Cdc42 (ab41429; Abcam, Cambridge, UK [RRID_726768]) and anti-Cdc42-GTP
(26905; New East Biosciences, PA, USA, [RRID:AB_1961759]). These primary antibodies were used
where appropriate in conjunction with Li-Cor IRDye 680 (anti-rabbit) [RRID:AB_621841] and IRDye
800 (anti-mouse) [RRID:AB_10793856] secondary antibodies, for use with the Li-Cor Infra-Red imag-
ing systems (Li-Cor Biosciences, Lincoln, Nebraska, USA) in Western blots or with Alexa Fluor 568
(anti-rabbit) [RRID:AB_143011] and Alexa Fluor 488 (anti-mouse) [RRID:AB_141626;Molecular
probes, Invitrogen, CA, USA] and/or anti-mouse CY5 (Jackson Immunoresearch, Newmarket, Suffolk,
UK[RRID:AB_[RRID:AB_2340152]) for fluorescence or confocal microscopy. We obtained Alexa 488-
labeled wheat germ agglutinin (WGA) from ThermoScientific Dublin (Product No W11261). DNA was
imaged with DAPI (Vector Scientific, Belfast, NI) while FITC-labeled phalloidin (p5282; Sigma-Aldrich,
Dorset, England) was used to image apical actin in organoid cultures. For PLA, studies we used
mouse anti-b-Arrestin1 from ThermoScientific, Paisley, UK with Duolink in situ fluorescence kits,
(Sigma-Aldrich, Dorset, England) according to manufacturer’s instructions. SiRNA oligonucleotides
targeted against b-Arrestin1 (Qiagen Flexitube; 1027417) or ARHGAP21 (Dharmacon SmartPool;
L-009382-01-0005) or nontargeting (NT) scrambled controls were purchased from Fisher Scientific,
Dublin, Ireland. The cell permeant b-Arrestin1-ARHGAP21 binding disruptor peptide [pep24 - based
on amino acids 1331 to 1355 within the ARHGAP21 GAP domain (Anthony et al., 2011)] and scram-
bled control peptide were purchased from EZ Biolabs, Carmel, IN 46032 USA. Pep24 and control
peptides were prepared in dimethyl sulfoxide (DMSO), according to manufacturer’s instructions. For
the pep24 experiments, cells were incubated in 2D or 3D cultures as outlined below for 48 hr, then
treated with either 10 mM pep24 or 10 mM control peptide. Incubations were continued for 24 hr for
assays of protein binding or Western blots in cell monolayers. In 3D morphogenesis assays, test and
control peptides were added to the media in the above concentrations, changed at 48 hr intervals
and effects on morphogenesis assessed at 4 days of culture.
Cell lines
Stable PTEN-deficient Caco-2 ShPTEN (ShPTEN) cells were generated by transfection of parental
Caco-2 cells (obtained from the American Type Culture Collection, Manassas, VA [RRID:CVCL_0025])
with replication-defective retroviral vectors encoding PTEN short hairpin RNA (ShRNA), using the
Phoenix retroviral expression system (Orbigen, San Diego, CA USA), as previously described
(Jagan et al., 2013a; Deevi et al., 2011). PTEN +/+ HCT116 [RRID:CVCL_0291] and PTEN -/-
HCT116 (here known as HCT116 and PTEN -/-) colorectal epithelial cells were a gift from Dr Tod
Waldman, Georgetown (Lee et al., 2004) and were cultured in McCoys 5A media supplemented
with 10% FCS (fetal calf serum), 1 mM L-glutamine and 1 mM sodium pyruvate. Caco-2 and ShPTEN
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 10% FCS, 1 mM
non-essential Amino Acids and 1 mM L-Glutamine at 37˚C in 5% CO2. In 3D cultures, Caco-2,
ShPTEN cells and subclones transfected with SiRNAs, PTEN C2 domain or empty vector (EV) control
constructs, were cultured embedded in a Matrigel matrix (BD Biosciences, Oxford, UK), as previously
described (Jagan et al., 2013a; Jagan et al., 2013b). Caco-2 and HCT116 cells were characterized
in terms of PTEN expression, AKT signaling, GTPase activation (Jagan et al., 2013a) and Caco-2
morphogenic growth (Jagan et al., 2013a). Furthermore, short tandem repeat (STR) profiling
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(Capes-Davis et al., 2013) conducted by LGC Standards, Middlesex, UK confirmed authenticity by
100% and 94% matches, respectively, between study parental Caco-2 and HCT116 cells and original
American Type Culture Collection (ATCC) derivatives.
Cell transfection
We carried out mammalian SiRNA and DNA transfections using RNAiMAX and X-tremeGENE trans-
fection reagents respectively, according to manufacturer’s protocols. Cells were plated at 2  105
cells/35 mm dish for 24 hr, then transfected with 10 mM siRNA or 500 ng DNA/2  105 cells for all
respective siRNA oligonucleotides or DNA constructs. Cells were incubated with RNA/RNAiMAX or
DNA/X-tremeGENE lipofectamine complexes for 48 hr, before lysis and probing. In 2 ShPTEN cells,
the stably expressed PTEN ShRNA targets a 58 base pair region within the PTEN phosphatase cod-
ing region and C2 domain constructs are unaffected (Boehm et al., 2005). In membrane localization
studies, PTEN-expressing and -deficient Caco-2 and HCT116 clones were transfected with b-
Arrestin1-mCherry against mCherry only controls. In expression, co-immunoprecipitation and mor-
phogenesis studies, ShPTEN cells were transiently transfected with empty vector (EV) only, the iso-
lated PTEN C2 domain (C2) or a C2 domain construct mutated at the CBR3 membrane-binding loop
[C2-MCBR3] (Lee et al., 1999) in pEGFP expression vectors.
PTEN mutants
PTEN-C124S-A4 and PTEN-C124S-T383A were generated by introduction of four alanine substitu-
tions at Ser380, Thr382, Thr383 and Ser385 and by alanine substitution at Thr383 only, respectively
(Raftopoulou et al., 2004) into lipid and protein phosphatase dead PTEN C124S (Maier et al.,
1999). These mutants suppress or enhance b-Arrestin1 binding, respectively (Lima-Fernandes et al.,
2011). PTEN-MCBR3, the isolated C2 domain and C2-MCBR3 were gifts from Dr N Leslie, Dundee
and were generated by replacement of 263-K-M-L-K-K-D-K-269 in the C2 domain CBR3 membrane
targeting loop with the 263-A-A-G-A-A-D-A-269 sequence (Lee et al., 1999), as previously
described (Jagan et al., 2013b). Sequence specificities of C2-MCBR3 and PTEN-MCBR3 mutants
were confirmed by sequencing studies.
Cell fractionation
We conducted these experiments using a subcellular fractionation kit (Thermo Fisher Scientific, Dub-
lin, Ireland) according to manufacturer’s protocol. Briefly, cells were trypsinized and lysed in cyto-
plasmic extraction buffer for 10 min at 4˚C, then centrifuged at 500 g for 5 min. The supernatant was
collected as the cytoplasmic fraction while the pellet was resuspended in membrane extraction
buffer, vortexed for 5 s and mixed gently for 10 min at 4˚C. The mix was centrifuged at 3000 g for 5
min and the supernatant was collected as the membrane fraction. In separate experiments, we con-
ducted protein extraction, Western blotting and co-immunoprecipitation (Co-IP) assays in isolated
cell membrane and cytosolic fractions. Equivalent amounts of membrane fraction and cytosol were
loaded in immunoblots and Co-Ips.
Protein extraction and western blotting
As previously described (Jagan et al., 2013a; Jagan et al., 2013b), proteins were resolved using gel
electrophoresis, followed by blotting onto nitrocellulose membranes. Membranes were probed
using antibodies as indicated in the text. Experiments were repeated in triplicate.
Co-immunoprecipitation (Co-IP)
Cells were lysed on ice in buffer containing 100 mM Tris-HCl, pH 7.5, 1% Triton X-100, 5 mM EDTA,
5 mM EGTA, 50 mM NaCl, 5 mM NaF, 1 mM Na3VO4 and protease inhibitor. Cell lysates were cen-
trifuged (for 10 mins at 15,000 g) and protein concentrations were measured by the BCA method.
1000 mg of protein was precleared overnight with control IgG and 15 ml of Protein A/G Sepharose
beads (Santa Cruz, Dallas, Texas, USA). The protein was then immunoprecipitated with the appropri-
ate antibody-beads conjugate and incubated on a rotating wheel for 2 hr. The beads were collected
by centrifugation and washed five times in wash buffer (50 mM Hepes, pH 7.4, 1% Triton X-100,
0.1%, SDS, 150 mM NaCl, 1 mM Na3VO4). The beads were subsequently resuspended in 40 ml
Laemmli sample buffer and processed for gel electrophoresis.
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GST-based-GTPase pulldown assays
Experiments were conducted as previously described (Deevi et al., 2016; Jagan et al., 2013b;).
Briefly, cells were grown on 90 mm dishes then lysed in buffer comprising 50 mM Tris-HCl (pH 7.5),
1% Triton X-100, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM Na3VO4 and protease inhibitor
cocktail (Roche) and centrifuged at 12,500 g for 10 min. We assayed the GTP-bound form of RhoA
by adding GST-Rhotekin fusion protein coupled with gluthathione sepharose 4B beads (Sigma-
Aldrich, Dorset, England) to 1 mg of cell lysate. Beads were collected after 1 hr by centrifugation,
washed x3 and resuspended in Laemmli buffer with 1 mM DTT. RhoA -GTP levels were then assayed
by western blotting. Experiments were repeated in triplicate.
Proximity ligation assays
We assessed protein-protein proximities using the Duolink II red kit (Sigma-Aldrich, Dorset, UK)
according to the manufacturer’s instructions. Briefly, we transfected PTEN-/- cells with GFP tagged-
EV or -PTEN constructs and cultured the cells in Millipore eight well chambers. After 24 hr, we fixed
the cells with 4% paraformaldehyde (PFA) at room temperature for 20 min. We then permeabilized
the cells with 0.05% TritonX100 in PBS for 10 min. Cells were blocked with immunofluorescence (IF)
buffer (Duolink, Sigma-Aldrich, Dorset), England for 2 hr according to manufacturer’s instructions
and incubated with primary antibody overnight at 4˚C. Cells were washed twice with buffer A, and
incubated with PLA probe, ligase and polymerase according to the manufacturer’s protocol. Finally,
cells were washed with buffer B and slides were mounted with a cover slip using Duolink in situ
mounting medium with DAPI.
BRET assays
BRET investigations were performed as described previously (Lima-Fernandes et al., 2014). Briefly,
HEK cells were transfected with the indicated plasmids 24 hr after seeding. At 24 hr post transfec-
tion, cells were detached, resuspended in full media, and distributed into poly-l-orthinine coated
white 96-well optiplates (Perkin Elmer). The following day, cells were washed with PBS and then
overlayed with HBSS. Coelenterazine h was added to a final concentration of 5 mM and incubated
for 3 min at 25˚C. BRET readings were collected using a Multimode Reader Mithras2 LB 943 (Bert-
hold Technologies). Substrate and light emissions were detected at 480 nm (Rluc) and 540 nm (YFP)
for 1 s. The BRET signal was calculated by ratio of the light emitted by YFP and the light emitted by
Rluc (YFP/Rluc). The ratio values were corrected by substracting background BRET signals detected
when Rluc-PTEN was expressed. mBRET values were calculated by multiplying these ratios by
1000. DmBRET values are shown to demonstrate the shift in BRET signal compared to wt signal,
which is set to zero, or between the two mutants (C124S-T383A and C124S-A4) that were tested.
Three-dimensional (3D) cultures and morphogenesis assays
Caco-2 and Caco-2 ShPTEN cells were cultured and embedded in Matrigel matrix (BD Biosciences,
Oxford, UK), then imaged by confocal microscopy as we previously described (Jagan et al., 2013a;
Jagan et al., 2013b). Briefly, 6  104 trypsinized cells were mixed with Hepes buffer (20 mM, pH
7.4) and Matrigel (40%) in a final volume of 100 ml, placed in each well of eight-well multichambers
(BD Falcon, Fisher Scientific, Dublin, Ireland), allowed to solidify for 30 min at 37˚C and subsequently
overlayed with 400 ml of media/well. We imaged the 3D cultures at progressive stages of morpho-
genesis as previously described (Jagan et al., 2013a; Jagan et al., 2013b).
Colorectal organoid cultures
We used C57B/6 wild-type mice (1–6 weeks old) for experiments and conducted all animal proce-
dures in accordance with local and national regulations. We isolated organoids as previously
described (Tait et al., 1994; Slorach et al., 1999). Briefly, murine colons were opened longitudinally,
cut into 0.5 cm fragments, washed 7–10 times in 1x HBSS (low calcium, low magnesium (Gibco-BRL),
2% D-glucose, 0.035% NaHCO3) to remove all luminal contents. The fragments were then finely
chopped with a scalpel and digested in HBSS solution containing collagenase and dispase I neutral
proteases (Sigma-Aldrich, Dorset, UK) at 1 mg/ml for 20 min at room temperature on a shaking plat-
form. Digestion was stopped by the addition of 30 ml DMEM/F12 culture medium (Life Technolo-
gies, Renfrew UK) supplemented with 5% FCS containing penicillin and streptomycin. Large
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fragments and muscle sheets were allowed to settle to the bottom of the flask. We removed the
supernatant containing the organoids and centrifuged it for 3 min at 250 rpm, to pellet the organo-
ids. We removed the supernatant and gently resuspended the organoid pellet in 20 ml of the
DMEM/F12 solution. We repeated the centrifugation step 5–6 times until the pellet contained a
homogeneously sized organoid preparation. Organoids thus prepared were resuspended in a 2x vol-
ume of Matrigel (growth factor reduced, phenol red free; BD Biosciences, Oxford UK) supplemented
with 50 ng/ml murine EGF, murine Noggin 100 ng/ml (PeproTech, NJ, USA) and 1 mg/ml human R--
Spondin, as indicated for organoid culture (Sato et al., 2011). Eight well multichambers were coated
with a thin layer of undiluted Matrigel and allowed to solidify. Organoid preparations in Matrigel
(100 ml suspension) were placed into each well, then overlaid with 250 mL/well culture medium (Dul-
becco’s modified Eagle medium/F12) supplemented with penicillin/streptomycin, 10 mmol/L HEPES,
Glutamax supplements 1 N2, 1  B27 [Invitrogen], 1 mmol/L N-acetylcysteine [Sigma]), 50 ng/ml
murine EGF, Noggin 100 ng/ml and 1 mg/ml human R-Spondin (Sato et al., 2011). We cultured the
organoids for 4 days with peptide treatments as defined.
Confocal immunofluorescence microscopy
Membrane and cytosolic localization of b-Arrestin1-mCherry or mCherry only were imaged against
Alexa 488-labelled WGA, a widely used fluorescent marker that binds to cell membranes
(Crossman et al., 2015) in Caco-2, ShPTEN, HCT116 and PTEN  /  cells, with or without LPA treat-
ment. We used a Leica SP8 confocal microscope and Leica LAS-X software for line scanning of fluo-
rescent images. Caco-2 ShPTEN (ShPTEN) glands and organoid cultures were incubated in 4% PFA
for 20 min and processed for immunofluorescence as previously described (Jagan et al., 2013a;
Deevi et al., 2016; Jagan et al., 2013b). Briefly, 3D cultures were fixed in PFA for 20 min at room
temperature and permeabilized for 10 min in 0.5% Triton X-100 in PBS. The 3D cultures were rinsed
with PBS/glycine buffer for 15 min to reduce autofluorescence and blocked by incubation in IF Buffer
(PBS with 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20)+10% goat serum, for 1–
1.5 hr at room temperature. Primary antibodies were diluted in blocking buffer and incubated over-
night at 4˚C. The 3D cultures were incubated with secondary antibodies and/or FITC-labeled phalloi-
din for 1 hr. DNA was stained using Vectashield mounting medium containing DAPI (Vector
Scientific, Belfast, NI). Sequential scan images were taken the midsection of glands/organoids at
room temperature using a Leica SP5 confocal microscope [RRID:SCR_012314] on a HCX PL APO
lambda blue 63  1.40 oil immersion objective at 1x or 2x zoom. Images were collected and scale
bars added using LAS AF confocal software (Leica) [RRID:SCR_013673]. We assessed effects of trans-
fection or treatment on signal intensity, spindle orientation, lumen formation and/or epithelial con-
figuration in in 3D glands or organoids at 4 days of culture. Because imaging for apical protein
kinase C zeta (PRKCZ) was unsuccessful in organoids, the apical domain was imaged using FITC-
labelled phalloidin as a marker of apical actin.
Assessment of mitotic spindle orientation
In cultured cells, centrosomes (Csms) were identified using anti-pericentrin (PCN) and microtubules
by anti-a-Tubulin antibodies, respectively, and we identified chromosomal DNA by DAPI staining.
We defined bipolar mitotic spindle architecture by convergence of microtubules towards each of 2
spindle poles, as we previously described (Deevi et al., 2016). Caco-2 and Caco-2 shPTEN glands
were cultured in Matrigel for 4 days, fixed with 4% PFA and stained with anti a-Tubulin, PRKCZ and
PCN primary antibodies. Gland midsections were imaged by confocal microscopy to identify cells
containing well-formed mitotic spindles, during metaphase or anaphase. Lines connecting each spin-
dle extremity were drawn using ImageJ and the line center was considered as the spindle midpoint.
Angles between spindle planes and lines connecting spindle midpoints to gland centres were mea-
sured, as outlined previously (Deevi et al., 2016; Jaffe et al., 2008). We used a similar approach or
imaging of organoid morphogenesis and identified apical domains and spindles using FITC-labeled
phalloidin and anti-a-Tubulin antibodies, respectively.
Image processing and statistical analysis
Confocal microscopy images were processed using Leica Fw4000 Imaging software and cropped
using Adobe Ilustrator [RRID:SCR_014198]. Confocal images were processed, merged and mean
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area quantified using LAS AF Leica imaging software, as previously described (Jagan et al., 2013a;
Jagan et al., 2013b). We assessed lumen formation, spindle orientation and signal intensities using
50, 15 or 10  3D Caco-2 or ShPTEN glandular cultures (glands) in triplicate for each experimental
condition, respectively. We selected glands with mitotic figures for spindle orientation assays. Orga-
noids were fewer in number and we assessed lumen formation and spindle orientation in 10 organo-
ids per experimental condition, in triplicate. Multicellular structures with single central lumens were
expressed as a percentage and spindle orientation angles relative to gland centres were calculated
using ImageJ.
Data analysis
Descriptive statistics were expressed as the mean ± sem. Statistical analyses were by one or two-way
ANOVA with the Tukey post hoc test or Student’s paired t test using Graphpad Prism software (v5;
Graphpad CA 92037 USA [RRID:SCR_002798]). Scatterplots and bar charts were used for display of
quantitative numerical or categorical data.
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